Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Narrative Review

Vol. 2 No. 2 (1996)

Prostate Specific Antigen (PSA): The Historical Perspective

  • T. Ming Chu, Ph.D.
DOI
https://doi.org/10.26443/mjm.v2i2.564
Submitted
November 7, 2020
Published
2020-12-01

Abstract

In 1970, shortly after joining Roswell Park Memorial Institute, the New York State institute for the study of malignant diseases, the author initiated investigations on the use of tumor cell products for diagnosis and therapy of cancer. Immunochemical approaches were used primarily to differentiate quantitatively or qualitatively normal cells from tumor cells. Prostate cancer was a major area of endeavor, with the goal to identify and characterize prostate tumor specific and associated antigens, and eventually to develop a simple but reliable blood test for prostate cancer. Prostate cancer research had not received much attention at the time this work was begun. The early studies focused upon, among others, prostatic acid phosphatase, alkaline phosphatase, and new prostate tumor markers. By the mid 1970s, three able investigators--Dr. Ching-Li Lee, Dr. Carl S. Killian, and Dr. Ming C. Wang--had joined the prostate cancer research team, and were invited to take charge of these three research projects, respectively.

References

  1. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen. Investigative Urology 17: 159-163; 1979.
  2. Wang MC, Valenzuela LA, Murphy GP, et al. A simplified purification procedure for human prostate antigen. Oncology 39: 1-5; 1982.
  3. Papsidero LD, Wang MC, Valenzuela LA, et al. A prostate antigen in sera of prostatic cancer patients. Cancer Research 40: 2428-2432; 1980.
  4. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay. Cancer Research 40: 4658-4662; 1980.
  5. Chu TM, Wang MC, Lee CL, et al. Enzyme markers for prostate cancer. Cancer Detection and Prevention 2: 693-706; 1979.
  6. Kuriyama M, Wang MC, Lee CL, et al. Multiple marker evaluation in prostate cancer using tissue specific antigens. Journal of the National Cancer Institute 68: 99-103; 1982.
  7. Kuriyama M, Wang MC, Lee CL, et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Research 41: 3874-3876; 1981.
  8. Wang MC, Loor RM, Li SL, et al. Physico-chemical characterization of prostate specific antigen purified from human prostate gland and seminal plasma. IRCS Journal of Medical. Science 11: 327-328; 1983.
  9. Ban Y, Wang MC, Watt KW, et al. The proteolytic activity of human prostate-specific antigen. Biochemical and Biophysical Research Communications. 123: 482-488; 1984.
  10. Watt K, Lee P, M'Timkulu T, et al. Human prostate-specific antigen: structural and functional similarity with serine protease. Proceedings of the National Academy of Sciences of the USA 83: 3166-3170; 1986.
  11. Papsidero LD, Croghan GA, Wang MC, et al. Monoclonal antibody (F5) to human prostate specific antigen. Hybridoma 2: 139-147; 1983.
  12. Chu TM, Kawinski E, Hibi N, et al. Prostate-specific antigenic domain of human prostate-specific antigen identified with monoclonal antibodies. Journal of Urology 141: 152-156; 1989.
  13. Papsidero LD, Kuriyama M, Wang MC, et al. Prostate specific antigen: A marker for human prostatic epithelial cells. Journal of the National Cancer Institute 66: 37-44; 1981.
  14. Papsidero LD., Wang MC, Kuriyama M, et al. Human prostate epithelial cell-specific antigen. In: Murphy GP, ed. The Prostatic Cell. New York: Alan R. Liss; 1981: 435-443.
  15. Nadji M, Tabei SZ, Castro A, et al. Prostatic specific antigen: An immunohistologic marker for prostatic neoplasms. Cancer 48: 1229-1232; 1981.
  16. Cooner WH, Mosley BR, Rutherford CL, et al. Clinical application of transrectal ultrasonography and prostate-specific antigen in the search for prostate cancer. Journal of Urology 139: 758-761; 1988.
  17. Catalona WJ, Smith DD, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New England Journal of Medicine. 324: 1156-1161; 1992.
  18. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate-specific antigen. Journal of Urology 147: 841-845; 1992.
  19. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270: 948-954; 1993.
  20. Egawa S, Suyama K, Ohori M, et al. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer 76: 463-472; 1995.
  21. Littrup PJ, Lee F and Mettlin CJ. Prostate cancer screening: Current trends and future implications. Ca: a Cancer Journal for Clinicians 42: 198-211; 1992.
  22. Mettlin CJ, Jones GW, Averette H, et al.Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancer. CA Cancer J. Clin. 43: 42-46; 1993.
  23. Potosky AL, Miller BA, Albertsen PC, et al.The role of increasing detection in the rising incidence of prostate cancer. Journal of the National Cancer Institute 273: 548-552; 1995.
  24. Jacobsen SJ, Katusic SK, Bergstralh EJ, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. Journal of the National Cancer Institute 274:1445-1449; 1995.
  25. Oesterling JE. Prostate-specific antigen. Improving its ability to diagnose early prostate cancer. Journal of the National Cancer Institute 267: 2236-2238; 1992.
  26. Schroder FH and Boyle P. Screening for prostate cancer-necessity or nonsense? European Journal of Cancer 29A: 656-661; 1993.
  27. Gohagan JK, Prorok PC, Kramer BS, et al.The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute. Cancer 75: 1869-1873; 1995.
  28. Wilt TJ and Barry MJ. The prostate cancer intervention versus observation trial (PIVOT). Urology International 3: 16-17; 1995.
  29. Krahn MD. The current PSA screening debate is not about PSA. Clinical Laboratory News Feb. 1-7; 1995.
  30. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. New England Journal of Medicine 330: 242-248; 1994.
  31. Wang MC, Papsidero LD, Kuriyama M, et al. Prostate antigen: A new potential marker for prostate cancer. Prostate 2: 89-96; 1981.
  32. Wang MC, Kuriyama M, Papsidero LD, et al. Prostate antigen of human cancer patients. In: Busch H and Yeoman LC, ed. Methods in Cancer Research. New York: Academic Press; 19: 179-197; 1982.
  33. Walsh PC. Prostate cancer kills: Strategy to reduce deaths. Urology 44: 463-466; 1994.

Downloads

Download data is not yet available.